New research has provided evidence that early clinical treatment of brain lesions can halt the progression of Alzheimer\'s disease. Working on genetically engineered mice that express the human disease genes, the researchers found that the use of specific antibodies to clear the hallmark amyloid plaques also reversed abnormalities arising from another hallmark of the disease--- neurofibrillary tangles. The findings are reported in the 5 August 2004 issue of *Neuron.*

Researchers also found that the earlier the treatment begins, the better the chances of success---findings that may have similar implications for people, emphasizing the need for better means of early diagnosis and treatment of patients with Alzheimer\'s disease.

Alzheimer\'s is the most common cause of dementia among the elderly in the United States, affecting 4.5-5 million adults. Both amyloid plaques and neurofibrillary tangles accumulate in specific brain regions critical to learning and memory. The belief that the accumulation of the plaques is the initiating trigger of the disease process constitutes the "amyloid cascade hypothesis." By showing that the progression of Alzheimer\'s can be stopped by early treatment of the plaques, the new findings support this hypothesis.

The researchers administered anti- ß-amyloid antibodies into the hippocampus of the mice and found that the plaques were cleared by three days, followed two days later by the clearance of the lesions caused by neurofibrillary tangles. Twenty-five days later, when the effect of the antibodies had diminished, the researchers found that amyloid plaques reemerged but the tangles did not.

"This suggests that these two pathologies are linked and that the development of the tangle pathology is dependent on the amyloid pathology," said group leader Frank LaFerla. "We found that when we cleared amyloid plaques from the brains of mice, the downstream consequences of the disease were lessened and even removed, provided the disease had not progressed to a certain advanced state. Our data are among the strongest experimental evidence to support the amyloid cascade hypothesis."

LaFerla\'s group is now investigating whether combined therapy---one aimed at clearing the plaques and one specifically targeted against the neurofibrillary tangles---will be effective. Such a therapy might help treat more advanced stages of Alzheimer\'s.

*Neuron, (2004), 43(3):321-32.* Doi not provided by the publisher.

New Approach Thwarts Cancer by Targeting Normal Cells {#cesec10}
=====================================================

Mayo Clinic and British researchers have developed an approach to cancer vaccines that purposely kills healthy cells to target the immune system against tumors. The new approach has eradicated skin cancer tumors in mice. The report appears in the September 2004 issue of *Nature Biotechnology.*

Skin cancer is currently the most common form of cancer in the United States, with an estimated one million new cases diagnosed annually. Normally, in conventional chemotherapy for cancer, the goal is to kill cancer cells and spare healthy cells. The new approach is turns the death of healthy cells into a therapeutic advantage by inflicting "inflammatory cell death." A cell-mediated immune response follows that targetted the tumor cells.

Specifically, the workers injected plasmid DNA encoding a melanocyte- targeted cytotoxic gene, along with heat shock protein 70 (hsp70) to attract T cells. They not only promoted inflammatory killing of normal melanocytes, but also induced a CD8+ T-cell--dependent, antigen-specific response that eradicated systemically established experimental B16 melanomas. This CD8+ T cell response was subsequently suppressed within a few days. Importantly, the approach avoided triggering autoimmune attacks, which are a common side effect of most cancer vaccine attempts. This is because the immune system appeared to send out regulatory T cells to inactivate the CD8 ^+^ T cell response. Multiple rounds of the treatment eradicated skin cancer in all the mice in the study, suggesting potential benefits to humans if the strategy can be transferred to cancer patients.

The new approach breaches a major obstacle to advancing cancer vaccine research from the laboratory into human trials. "We\'re very encouraged by these results because our main interest is in generating cancer vaccines that will stimulate the immune system to recognize tumors and eradicate them. We hope our novel approach will be a more specific, and therefore gentler therapy for patients," says Mayo immunologist and lead researcher, Richard Vile.

*Nature Biotechnology,* online edition, doi: 10.1038/nbt999

Glycan Arrays Probe Autoimmunogenicity of Monkey SARS Vaccine {#cesec20}
=============================================================

Researchers in New York City and Guangzhou, China have applied carbohydrate microarray technology to study an inactivated SARS-coron- avirus (SARS-CoV) vaccine and have discovered an autoimmunogenic activity in this pathogen. The research appears in the July 2004 issue of *Physiological Genomics.*

The workers previously utilized nitrocellulose-coated glass slides as substrates to immobilize carbohydrate antigens for high-throughput construction of carbohydrate arrays.

Using this technology, they constructed a glycan array to display a collection of carbohydrate antigens, including microbial and plant-derived polysaccharides, as well as cellular glycan complex carbohydrates.

Using the glycan microarrays, the workers characterized the carbohydrate binding activity of SARS-CoV neutralizing antibodies elicited by an inactivated SARS vaccine produced in monkey cells. They found autoantibody reactivity that was directed toward the complex carbohydrate of a human serum glycoprotein, ASOR (asialo-orosomucoid). The lectin, PHA- L, is specific for a defined complex carbohydrate of ASOR, and was shown to specifically stain SARS-CoV-infected cells. The results suggest that the virus expresses structures that mimic the human ASOR glycan.

The authors suggest that the findings provide sufficient immunologic evidence that a viral-expressed carbohydrate structure is responsible for the induction of anti-ASOR autoimmunity in vaccinated animals. These observations raise concerns on human use of the whole virus-based SARS vaccine that is produced in monkey Vero E6 cells. It may be necessary to eliminate the undesired autoimmunogenic activity of the preparation of inactivated SARS-CoV. It may also be possible to identify an alternative cell line or to genetically modify the Vero E6 cell line by altering its glycosylation pathway, thereby producing vaccines with enhanced efficacy without autoimmunogenic activity.

It will also be important to examine whether naturally occurring SARS- CoV expresses the autoimmunogenic reactivities that are found in the monkey-cell produced viruses. The authors pointed out that a species-associated variation in protein glycosylation might result in significant differences in sugar chains expression by the SARS viruses. To clarify whether "humanized" SARS viruses are autoimmunogenic to humans, the authors suggest investigation of the serum antibody profiles of SARS patients and vaccinated subjects using glycan arrays and other immunological tools.

*Physiological Genomics,* online edition, doi: 10.1152/physiolgenomics.00102.2004

"Smart Gene Therapy" Protects against Ischemic Damage in Rats {#cesec30}
=============================================================

Early intervention with a kind of "smart gene therapy" might help prevent the organ damage commonly suffered by heart attack victims, according to a new study. The therapy makes use of a therapeutic cassette that incorporates a genetic "sensor" that recognizes and responds to the oxygen deprivation that follows the reduced blood flow, or ischemia, from coronary artery disease and heart attack. The study appears in the online edition of the *Proceedings of the National Academy of Sciences* the week of 2 August 2004

Using an AAV vector, the researchers injected the gene construct into the heart, liver and skeletal muscle of three rats. Five weeks later, they restricted blood flow to the animals' organs by clamping key arteries for a period of an hour and then examined the organs for evidence of injury. As soon as the oxygen declines, the sensor turns on the therapeutic gene, heme-oxygenase 1, which has been shown to protect heart cells during ischemia. The researchers found that the strategy protected the cells from much of the damage associated with ischemia. The strategy might prove useful for any condition in which tissues are susceptible to loss of blood supply, including stroke, shock, trauma and sepsis, the researchers said.

Such a therapy could offer a significant advance over available methods for treating heart patients, which are limited in their ability to provide treatment in the narrow window of time before irreversible heart damage occurs, said lead researcher Victor Dzau. "While drugs that can protect heart muscle are available, most patients barely make it to the hospital in time to take advantage of them," Dzau said. "This smart gene therapy could be administered preemptively to high- risk patients months before they develop a heart attack to provide them with long-term protection from ischemic injury."

In addition, one month later the untreated animals exhibited severe thinning of the heart wall and reduced heart function compared to those that received the gene therapy. After four months, the untreated rats still showed marked thinning of the heart wall, while those treated with the gene construct showed virtually no evidence of damage, Dzau said. The team will next verify its results in another animal model. If the findings hold, Dzau predicts the therapy could be ready to enter a phase I clinical trial in human patients in as little as a year.

*The Proceedings of the National Academy of Sciences* online, doi: 10.1073/pnas.0404606101
